Media
January 2, 2012 | source: Biocentury
Topical formulation of peptide 144 transforming growth factor (TGF) beta 1 inhibitor
More information
November 21, 2011 | source: Biocentury
Digna regained exclusive rights from Isdin to P144
More information
November 15, 2011 | source: European Biotechnology News
Digna Biotech regains rights for inhibitor for systemic skin sclerosis
More information
November 15, 2011 | source: Bioworld
Digna regained rights to disitertide (p144) from skin care company Isdin
More information
November 14, 2011 | source: Firstword
Digna Biotech regains all rights to Disitertide (P144) to treat skin conditions and will share with ISDIN potential revenues
More information
November 14, 2011 | source: GEN
Digna Biotech Takes Back Rights to Peptide Therapeutic for Skin Disorders
More information
September 26, 2011 | source: Biocentury
FDA and the European Commission granted Orphan Drug designation for Digna’s cardiotrophin-1 to treat acute liver failure.
More information
September 22, 2011 | source: News Medical
Digna Biotech receives FDA Orphan Drug status for cardiotrophin-1 to treat ALF
More information
September 21, 2011 | source: FirstWord Executive Plus Edition
FDA Grants Cardiotrophin-1 Orphan Drug Status for Acute Liver Failure Treatment
More information
September 13, 2011 | source: Science Newsline
Cardiotrophin 1 Shows Promising Results for Treatment of Obesity And Metabolic Syndrome
More information
September 13, 2011 | source: Science News. Insights into European Science
Cardiotrophin 1 shows promising results for treatment of obesity and metabolic syndrome
More information
September 13, 2011 | source: Biotechnology-Europe
Cardiotrophin 1 shows promising results for treatment of obesity and metabolic syndrome
More information
August 25, 2011 | source: Nature/SciBX
Cardiotrophin workout
More information
July 4, 2011 | source: Biocentury
Digna/Flamel Deal
More information
June 27, 2011 | source: First Word Executive Plus Edition
Flamel Technologies and Digna Biotech Announce Multiple Product Development Agreement
More information
April 21, 2011 | source: SciBX
CD40; toll-like receptor 3 (TLR3); TLR4
More information
September 10, 2009
Biotecnol, Digna Biotech and Genentech enter into an Exclusive License and Option Agreement, for treatment of life-threatening liver diseases
More information
May 28, 2008 | source: Diario Expansión. 28 may 2008
The CIMA, leads again the ranking of the sector with the record of fourteen inventions in 2007.
More information
April 24, 2008 | source: media: www.diariodenavarra.es
The transplant in advanced hepatic cancer obtains good results
More information
April 24, 2008
The biotechnological dutch AMT will develop patents of the gene therapy department of the CIMA (Universidad de Navarra)
More information
October 17, 2007 | source: Expansión. 17th October 2007, Empresas, p. 16.
Small giants of Spanish Biotechnology (II): Digna Biotech marca el modelo del sector
More information
© Digna Biotech · Legal information · Company associated to ASEBIO 